Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.

Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., et al. (2015). Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 26(7), 545-553 [10.1016/j.ejim.2015.04.022].

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

SINICO, RENATO ALBERTO;
2015

Abstract

Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.
Articolo in rivista - Articolo scientifico
Anti-neutrophil cytoplasm antibody-associated vasculitis; Asthma; Churg-Strauss syndrome; Eosinophilia; Eosinophilic granulomatosis with polyangiitis; Recommendations; Advisory Committees; Churg-Strauss Syndrome; Consensus; Disease Management; Europe; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Rituximab; United States; Internal Medicine; Medicine (all)
English
545
553
9
Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., et al. (2015). Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 26(7), 545-553 [10.1016/j.ejim.2015.04.022].
Groh, M; Pagnoux, C; Baldini, C; Bel, E; Bottero, P; Cottin, V; Dalhoff, K; Dunogué, B; Gross, W; Holle, J; Humbert, M; Jayne, D; Jennette, J; Lazor, R; Mahr, A; Merkel, P; Mouthon, L; Sinico, R; Specks, U; Vaglio, A; Wechsler, M; Cordier, J; Guillevin, L
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/139205
Citazioni
  • Scopus 254
  • ???jsp.display-item.citation.isi??? 239
Social impact